The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
PMV Pharmaceuticals, Inc
PMV Pharmaceuticals, Inc
NeoImmuneTech
Monte Rosa Therapeutics, Inc
AstraZeneca
Radiopharm Theranostics, Ltd
Incyte Corporation
TransThera Sciences (Nanjing), Inc.
Klus Pharma Inc.
Cybrexa Therapeutics
Cyteir Therapeutics, Inc.
National Cancer Institute (NCI)
Sellas Life Sciences Group
Salubris Biotherapeutics Inc
TransThera Sciences (Nanjing), Inc.
Incyte Corporation
Ipsen
Gilead Sciences
Western Regional Medical Center
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.